|
1
|
John DT, Petri WA and Markell EK: Voge M.
Markell and Voge's Medical Parasitology. 9th eddition. Elsevier
Health Sciences, St. Louis. 2006.
|
|
2
|
Choo JD, Lee JS, Kang JS, Lee HS, Yeom JY
and Lee YH: Inhibitory effects of Toxoplasma antigen on
proliferation and invasion of human glioma cells. J Korean
Neurosurg Soc. 37:129–136. 2005.
|
|
3
|
Kim JO, Jung SS, Kim SY, Kim TY, Shin DW,
Lee JH and Lee YH: Inhibition of Lewis lung carcinoma growth by
Toxoplasma gondii through induction of Th1 immune responses
and inhibition of angiogenesis. J Korean Med Sci. 22:S38–S46.
2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pyo KH, Jung BK, Chai JY and Shin EH:
Suppressed CD31 expression in sarcoma-180 tumors after injection
with Toxoplasma gondii lysate antigen in BALB/c mice. Korean
J Parasitol. 48:171–174. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Fox BA, Sanders KL and Bzik DJ:
Non-replicating Toxoplasma gondii reverses tumor-associated
immunosuppression. Oncoimmunology. 2(e26296)2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Darani HY, Shirzad H, Mansoori F,
Zabardast N and Mahmoodzadeh M: Effects of Toxoplasma gondii
and Toxocara canis antigens on WEHI-164 fibrosarcoma growth in a
mouse model. Korean J Parasitol. 47:175–177. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Baird JR, Byrne KT, Lizotte PH,
Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik
DJ, Bosenberg M, et al: Immune-mediated regression of established
B16F10 melanoma by intratumoral injection of attenuated
Toxoplasma gondii protects against rechallenge. J Immunol.
190:469–478. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Baird JR, Fox BA, Sanders KL, Lizotte PH,
Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR,
Fiering S and Bzik DJ: Avirulent Toxoplasma gondii generates
therapeutic antitumor immunity by reversing immunosuppression in
the ovarian cancer microenvironment. Cancer Res. 73:3842–3851.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ubillos L, Freire T, Berriel E, Chiribao
ML, Chiale C, Festari MF, Medeiros A, Mazal D, Rondán M,
Bollati-Fogolín M, et al: Trypanosoma cruzi extracts elicit
protective immune response against chemically induced colon and
mammary cancers. Int J Cancer. 138:1719–1731. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen L, He Z, Qin L, Li Q, Shi X, Zhao S,
Chen L, Zhong N and Chen X: Antitumor effect of malaria parasite
infection in a murine Lewis lung cancer model through induction of
innate and adaptive immunity. PLoS One. 6(e24407)2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chookami MB, Sharafi SM, Sefiddashti RR,
Jafari R, Bahadoran M, Pestechian N and Yousofi Darani H: Effect of
two hydatid cyst antigens on the growth of melanoma cancer in
C57/black mice. J Parasit Dis. 40:1170–1173. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Berriel E, Russo S, Monin L, Festari MF,
Berois N, Fernández G, Freire T and Osinaga E: Antitumor activity
of human hydatid cyst fluid in a murine model of colon cancer.
ScientificWorldJournal 230176. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Karadayi S, Arslan S, Sumer Z, Turan M,
Sumer H and Karadayi K: Does hydatid disease have protective
effects against lung cancer? Mol Biol Rep. 40:4701–4704.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kallinikova VD, Batmonkh Ts, Kosobokova
EN, Pakhorukova LV, Ogloblina TA, Kravtsov EG, Karpenko LP and
Matekin PV: Antibodies against Trypanosoma cruzi in intact
mice and their oncoprotective effect. Med Parazitol (Mosk).
1:11–15. 2008.(In Russian). PubMed/NCBI
|
|
15
|
Zenina AV, Kravtsov EG, Tsetsegsaikhan B,
Yashina NV, Dalin MV, Karpenko LP, Sheklakova LA and Kallinikova V:
The study of immunological component in antitumor effect of
Trypanosoma cruzi. Bull Exp Biol Med. 145:352–354.
2008.PubMed/NCBI
|
|
16
|
Ubillos L, Medeiros A, Cancela M,
Casaravilla C, Saldaña J, Domínguez L, Carmona C, Le Pendu J and
Osinaga E: Characterization of the carcinoma-associated Tk antigen
in helminth parasites. Exp Parasitol. 116:129–136. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Thors C, Jansson B, Helin H and Linder E:
Thomsen-Friedenreich oncofetal antigen in Schistosoma mansoni:
Localization and immunogenicity in experimental mouse infection.
Parasitology. 132:73–81. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Daneshpour S, Bahadoran M, Hejazi SH,
Eskandarian AA, Mahmoudzadeh M and Darani HY: Common antigens
between hydatid cyst and cancers. Adv Biomed Res.
5(9)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Darani HY, Ahmadi F, Zabardast N, Yousefi
HA and Shirzad H: Development of a latex agglutination test as a
simple and rapid method for diagnosis of Trichomonas
vaginalis infection. Avicenna J Med Biotechnol. 2:63–66.
2010.PubMed/NCBI
|
|
20
|
Sharafi SM, Shirzad H, Khanahmad H, Ataei
B and Darani HY: Monoclonal antibodies production against a 40 KDa
band of hydatid cyst fluid. Recent Pat Biotechnol. 12:57–64.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Salanti A, Clausen TM, Agerbæk MØ, Al
Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg
BJ, et al: Targeting human cancer by a glycosaminoglycan binding
malaria protein. Cancer Cell. 28:500–514. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Baldus SE, Engelmann K and Hanisch FG:
MUC1 and the MUCs: A family of human mucins with impact in cancer
biology. Crit Rev Clin Lab Sci. 41:189–231. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sharafi SM, Rafiei R, Rafiei R, Hadipour
M, Shirzad H, Khanahmad H and Darani HY: A Nonglycosylated 27 kDa
molecule as common antigen between human breast cancer and
Echinococcus granulosus hydatid cyst wall. Adv Breast Cancer
Res. 5:90–95. 2016. View Article : Google Scholar
|
|
24
|
Porter R and Reid K: Activation of the
complement system by antibody-antigen complexes: the classical
pathway. Advances in protein chemistry. Adv Protein Chem. 33:1–71.
1979.
|
|
25
|
Chari RV: Targeted cancer therapy:
Conferring specificity to cytotoxic drugs. Acc Chem Res. 41:98–107.
2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Damle NK: Tumour-targeted chemotherapy
with immunoconjugates of calicheamicin. Expert Opin Biol Ther.
4:1445–1452. 2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kovtun YV and Goldmacher VS: Cell killing
by antibody-drug conjugates. Cancer Lett. 255:232–240.
2007.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wu AM and Senter PD: Arming antibodies:
Prospects and challenges for immunoconjugates. Nat Biotechnol.
23:1137–1146. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Trail PA, King HD and Dubowchik GM:
Monoclonal antibody drug immunoconjugates for targeted treatment of
cancer. Cancer Immunol Immunother. 52:328–337. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sahin U, Türeci Ö, Usener D, Fritz S,
Uherek C, Brandenburg G, Geppert HG, Schroeder Anja K and Thiel P:
Monoclonal antibodies against claudin-18 for treatment of cancer.
Google Patents EP 2311879 A2. Filed November 24 2005; issued April
20. 2011.
|
|
31
|
Patil R, Holler E, Black KL and Ljubimova
JY: Drug delivery of Temozolomide for systemic based treatment of
cancer. Google Patents US8785371B2. Filed December 10, 2009; issued
November 28. 2017.
|
|
32
|
Lallatin NC: Monoclonal antibodies to
human thymidine kinase to treat cancer. Google Patents. 2013.
|
|
33
|
Parmiani G, Castelli C, Dalerba P,
Mortarini R, Rivoltini L, Marincola FM and Anichini A: Cancer
immunotherapy with peptide-based vaccines: What have we achieved?
Where are we going? J Natl Cancer Inst. 94:805–818. 2002.PubMed/NCBI
|
|
34
|
Marchand M, van Baren N, Weynants P,
Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F,
Humblet Y, et al: Tumor regressions observed in patients with
metastatic melanoma treated with an antigenic peptide encoded by
gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:219–230.
1999.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Weber JS, Hua FL, Spears L, Marty V,
Kuniyoshi C and Celis E: A phase I trial of an HLA-A1 restricted
MAGE-3 epitope peptide with incomplete Freund's adjuvant in
patients with resected high-risk melanoma. J Immunother.
22:431–440. 1999.PubMed/NCBI
|
|
36
|
Valmori D, Fonteneau J-F, Lizana CM,
Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini
JC and Romero P: Enhanced generation of specific tumor-reactive CTL
in vitro by selected Melan-A/MART-1 immunodominant peptide
analogues. J Immunol. 160:1750–1758. 1998.PubMed/NCBI
|
|
37
|
Schulz M, Zinkernagel RM and Hengartner H:
Peptide-induced antiviral protection by cytotoxic T cells. Proc
Natl Acad Sci USA. 88:991–993. 1991.PubMed/NCBI
|
|
38
|
Kast WM, Roux L, Curren J, Blom HJ,
Voordouw AC, Meloen RH, Kolakofsky D and Melief CJ: Protection
against lethal Sendai virus infection by in vivo priming of
virus-specific cytotoxic T lymphocytes with a free synthetic
peptide. Proc Natl Acad Sci USA. 88:2283–2287. 1991.PubMed/NCBI
|
|
39
|
Mandelboim O, Vadai E, Fridkin M,
Katz-Hillel A, Feldman M, Berke G and Eisenbach L: Regression of
established murine carcinoma metastases following vaccination with
tumour-associated antigen peptides. Nat Med. 1:1179–1183.
1995.PubMed/NCBI
|
|
40
|
Noguchi Y, Chen YT and Old LJ: A mouse
mutant p53 product recognized by CD4+ and
CD8+ T cells. Proc Natl Acad Sci USA. 91:3171–3175.
1994.PubMed/NCBI
|
